ArticleAnnual review of cancer biology2026
Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.
Article in Annual review of cancer biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diffuse large B cell lymphoma (DLBCL) is a clinically and genetically heterogeneous disease. Molecular profiling studies in DLBCL have identified three distinct disease subtypes using gene expression profiling, whereas mutation analysis of tumors has identified at least six separate subtypes. Although each classifier predicts clinical responses to immunochemotherapy and targeted therapies, molecular profiling is not universally performed or uniformly implemented. In this review, we focus on the biology of the LymphGen algorithm defined genetic subtypes revealed by genomic, transcriptomic, and single-cell profiling. We highlight recent advances in understanding the major drivers of disease and discuss how different mutations promote common hallmarks of cancer that are vulnerable to precision medicine agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.